Table 2.
The correlation between HDAC3 expression and clinicopathological parameters.
| Clinicopathological parameter | Cases | HDAC3 high No. (%) |
HDAC3 low No. (%) |
P-value |
|---|---|---|---|---|
| ALL cases | 143 | 97 (67.8) | 46 (32.2) | |
| Age | 0.475 | |||
| <50 | 62 | 40 (64.5) | 22 (35.5) | |
| ≥50 | 81 | 57 (70.4) | 24 (29.6) | |
| PT stage | 0.040* | |||
| PT1 | 32 | 16 (50.0) | 16 (50.0) | |
| PT2 | 96 | 71 (74.0) | 25 (26.0) | |
| PT3 | 14 | 10 (71.4) | 4 (28.6) | |
| Lymph nodes | 0.413 | |||
| Negative | 44 | 34 (77.3) | 10 (22.7) | |
| Positive | 88 | 61 (69.3) | 27 (30.7) | |
| ER | 0.036** | |||
| Negative | 54 | 43 (79.6) | 11 (20.4) | |
| Positive | 79 | 49 (62.0) | 30 (38.0) | |
| PR | 0.024** | |||
| Negative | 51 | 40 (78.4) | 11 (21.6) | |
| Positive | 83 | 49 (59.0) | 34 (41.0) | |
| HER2 status | 0.037** | |||
| Negative | 92 | 57 (62.0) | 35 (38.0) | |
| Positive | 50 | 40 (80.0) | 10 (20.0) | |
| Clinical stage | 0.046* | |||
| I | 10 | 4 (40.0) | 6 (60.0) | |
| II | 83 | 62 (74.7) | 21 (25.3) | |
| III | 47 | 29 (61.7) | 18 (38.3) | |
| Histological grade | 0.103 | |||
| G1 | 5 | 2 (40.0) | 3 (60.0) | |
| G2 | 111 | 80 (73.1) | 31 (27.9) | |
| G3 | 27 | 15 (55.6) | 12 (44.4) |
*
Chi-square test;
**
Fisher exact test.